Source - RNS
RNS Number : 3959M
Vernalis PLC
12 October 2016
 

 

12 October 2016

LSE: VER

Vernalis plc

Director/PDMR Dealing

 

 

 

Vernalis plc (LSE: VER) ("the Company") announces that David Mackney, Chief Financial Officer of the Company was today allotted 48,630 ordinary shares of 1 pence each ("Ordinary Shares") following his exercise of options under the Company's 2007 Bonus Long-Term Incentive Plan ("LTIP").  Mr Mackney subsequently sold 27,233 Ordinary Shares to settle payment of all tax and NI requirements in relation to the exercise as set out in the notification below.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1.

Details of PDMR / person closely associated with them ("PCA")

a)

Name

David Mackney

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Vernalis plc

b)

Legal Entity Identifier

n/a

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00B3Y5L754

b)

Nature of the transaction

Exercise and Allotment of Ordinary Shares under the Company's LTIP

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1 pence

48,630 Ordinary Shares

d)

Aggregated information

-     Aggregated volume

-     Aggregated price

-     Aggregated total

 

N/A - single transaction

e)

Date of the transaction

12 October 2016 (UK)

f)

Place of the transaction

Outside a trading venue

5.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary shares of 1 pence each ("Ordinary Shares")

GB00B3Y5L754

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

39.07 pence

27,233 Ordinary Shares

d)

Aggregated information

-     Aggregated volume

-     Aggregated price

-     Aggregated total

 

N/A - single transaction

e)

Date of the transaction

12 October 2016 (UK)

f)

Place of the transaction

London Stock Exchange, AIM

 

-- ends -

 

Enquiries:

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer


David Mackney, Chief Financial Officer

 


Canaccord Genuity Limited (Nominated Adviser and Joint Broker):

+44 (0) 20 7523 8000

Dr Julian Feneley


Rupert Winckler


Henry Fitzgerald-O'Connor


Emma Gabriel

 


Shore Capital (Joint Broker):

+44 (0)20 7408 4090

Bidhi Bhoma


Toby Gibbs

 


FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell


Simon Conway


 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development.  The Group has three approved products: Tuzistra® XR, targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.

For further information about Vernalis, please visit www.vernalis.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGGGMAUUPQGAP

Related Charts

Vernalis (VER)

-0.25p (-0.74%)
delayed 09:18AM